Posters presented at the 2023 Fall Clinical Dermatology Conference evaluated how label warnings may affect new treatment initiation and real-word switching patterns for patients starting risankizumab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback